Estimated Time per Response: 0.17 hours–0.44 hours.

Frequency of Response: On occasion reporting requirement; third party disclosure requirement, recordkeeping & other (5 & 10 yrs).

Obligation to Respond: Required to obtain or retain benefits. Statutory authority for this collection of information is contained in 47 U.S.C. 154, 301 sections 4 and 301.

Total Annual Burden: 57,218 hours. Total Respondent Cost: \$4,550,000. Needs and Uses: FCC 605 application is a consolidated application form for Ship, Aircraft, Amateur, Restricted and Commercial Radio Operators, and General Mobile Radio Services and is used to collect licensing data for the Universal Licensing System. The Commission is requesting OMB approval for a minor revision to the reporting, recordkeeping and/or third party disclosure requirements. The Commission is removing Certification #3 for the General Mobile Radio Service, as well as making minor clarifications to

The data collected on this form includes the Date of Birth for Commercial Operator licensees however this information will be redacted from public view.

the general filing instructions.

The FCC uses the information in FCC Form 605 to determine whether the applicant is legally, technically, and financially qualified to obtain a license. Without such information, the Commission cannot determine whether to issue the licenses to the applicants that provide telecommunication services to the public, and therefore, to fulfill its statutory responsibilities in accordance with the Communications Act of 1934, as amended. Information provided on this form will also be used to update the database and to provide for proper use of the frequency spectrum as well as enforcement purposes.

Federal Communications Commission. **Marlene Dortch**,

Secretary, Office of the Secretary.

[FR Doc. 2023–13408 Filed 6–22–23; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL ELECTION COMMISSION

Sunshine Act Meetings

FEDERAL REGISTER CITATION NOTICE OF PREVIOUS ANNOUNCEMENT: 88 FR 39847. PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: Thursday, June 22, 2023 at 10:30 p.m.

CHANGES IN THE MEETING: The time of the meeting is 10:30 a.m.

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694–1220.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Submitted: June 20, 2023.

Laura E. Sinram,

Secretary and Clerk of the Commission. [FR Doc. 2023–13448 Filed 6–21–23; 11:15 am] BILLING CODE 6715–01–P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Savings and Loan Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Home Owners' Loan Act (12 U.S.C. 1461 et seq.) (HOLA), Regulation LL (12 CFR part 238), and Regulation MM (12 CFR part 239), and all other applicable statutes and regulations to become a savings and loan holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a savings association.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on whether the proposed transaction complies with the standards enumerated in the HOLA (12 U.S.C. 1467a(e)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 10(c)(4)(B) of the HOLA (12 U.S.C. 1467a(c)(4)(B)). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than July 24, 2023.

A. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President) One Memorial Drive, Kansas City, Missouri 64198. Comments can also be sent electronically to

KCApplicationComments@kc.frb.org:
1. Central Plains Bancshares, Inc.,
Grand Island, Nebraska; to become a
savings and loan holding company by
acquiring Home Federal Savings and
Loan Association of Grand Island,
Grand Island, Nebraska, in connection
with the conversion of Home Federal
Savings and Loan Association of Grand
Island from mutual to stock form.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2023–13405 Filed 6–22–23; 8:45 am] BILLING CODE P

FEDERAL TRADE COMMISSION

[File No. 192 3170]

Vitagene, Inc.; Analysis of Proposed Consent Order To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement; request for comment.

SUMMARY: The consent agreement in this matter settles alleged violations of Federal law prohibiting unfair or deceptive acts or practices. The attached Analysis of Proposed Consent Order to Aid Public Comment describes both the allegations in the complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before July 24, 2023.

ADDRESSES: Interested parties may file comments online or on paper by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Please write "Vitagene, Inc.; File No. 192 3170" on your comment and file your comment online at https:// www.regulations.gov by following the instructions on the web-based form. If you prefer to file your comment on paper, please mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC-5610 (Annex V), Washington, DC 20580

FOR FURTHER INFORMATION CONTACT:

James Trilling (202–326–3497), or Elisa Jillson (202–326–3001), Attorneys, Division of Privacy and Identity Protection, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Ave. NW, Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule § 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of 30 days. The following Analysis to Aid Public Comment describes the terms of the consent agreement and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained at https://www.ftc.gov/newsevents/commission-actions.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before July 24, 2023. Write "Vitagene, Inc.; File No. 192 3170" on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the https://www.regulations.gov website.

Because of heightened security screening, postal mail addressed to the Commission will be subject to delay. We strongly encourage you to submit your comments online through the https://www.regulations.gov website. If you prefer to file your comment on paper, write "Vitagene, Inc.; File No. 192 3170" on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC—5610 (Annex V), Washington, DC 20580.

Because your comment will be placed on the publicly accessible website at https://www.regulations.gov, you are solely responsible for making sure your comment does not include any sensitive or confidential information. In particular, your comment should not include sensitive personal information, such as your or anyone else's Social Security number; date of birth; driver's license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure your comment does not include sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any "trade secret or any commercial or financial information which . . . is privileged or confidential"—as provided by section

6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule § 4.10(a)(2), 16 CFR 4.10(a)(2)—including competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled "Confidential," and must comply with FTC Rule § 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule § 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted on the https://www.regulations.gov website—as legally required by FTC Rule § 4.9(b)we cannot redact or remove your comment from that website, unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule § 4.9(c), and the General Counsel grants that request.

Visit the FTC website at http:// www.ftc.gov to read this document and the news release describing the proposed settlement. The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding, as appropriate. The Commission will consider all timely and responsive public comments it receives on or before July 24, 2023. For information on the Commission's privacy policy, including routine uses permitted by the Privacy Act, see https://www.ftc.gov/site-information/ privacy-policy.

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission (the "Commission") has accepted, subject to final approval, an agreement containing a consent order from 1Health.io Inc. (formerly known as, and doing business as, Vitagene, Inc.) ("Vitagene"). The proposed consent order ("proposed order") has been placed on the public record for 30 days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After 30 days, the Commission again will review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement's proposed order.

Since 2015, Vitagene has sold "DNA Health Test Kits" to consumers. In each DNA Health Test Kit, Vitagene instructs the consumer to provide a saliva sample by mail. Vitagene contracts with a testing lab to analyze the sample and map a portion of the consumer's genetic code.

Vitagene combines the testing lab's DNA analysis with the consumer's answers to an online "health questionnaire" that probes the individual's health history, lifestyle, and family health history. Using this information, Vitagene generates reports about the consumer's health and wellness ("Health Reports") and ancestry. Vitagene also sells to the consumer Health Reports that it creates by using the consumer's answers to an online "lifestyle questionnaire" and raw DNA data that the consumer sends to Vitagene after the consumer has obtained DNA tests from certain companies other than Vitagene. The retail cost for a package that includes a Health Report has ranged from \$29 to \$259, with higher-priced packages including add-ons such as subscriptions to personalized vitamin packs and nutritional coaching.

The Health Reports that Vitagene creates contain numerous facts about the consumer's genetics and health. For example, one type of Health Report first lists the consumer's name, date of birth, and referring doctor or dietician, and then identifies salient genotype data, pertinent questionnaire answers, and, based on the genotype data and questionnaire answers, the level of risk for having or developing certain health conditions, such as high LDL cholesterol, high triglycerides, obesity, or blood clots.

As part of its information technology infrastructure, Vitagene stores consumers' health and genetic information in the Amazon Web Services ("AWS") Simple Storage Service (the "Amazon S3 Datastore") in virtual containers, called "buckets." The files Vitagene has stored in Amazon S3 Datastore buckets include, among other things, consumers' Health Reports; genotype data called single-nucleotide polymorphisms ("SNPs"), which are the most common type of genetic variation among people; and other raw genotype data.

The proposed complaint alleges that, despite the fact that Vitagene has stored consumers' sensitive personal information in the Amazon S3 Datastore, Vitagene did not uniformly apply basic safeguards to the data in each of its Amazon S3 Datastore buckets. In particular, the proposed complaint alleges that, in or about 2016,

Vitagene created a publicly accessible bucket in which the company stored Health Reports for at least 2,383 consumers and a publicly accessible bucket in which it stored raw genetic data (sometimes accompanied by first name) for at least 227 consumers. The proposed complaint alleges that Vitagene's failure to use access controls to restrict access to this sensitive data, encrypt it, log or monitor access to it, or inventory it, to help ensure ongoing security resulted in Vitagene publicly exposing the data until July 2019. According to the proposed complaint, between July 2017 and June 2019, Vitagene received at least three warnings that it was storing consumers' unencrypted health, genetic, and other personal information in publicly accessible buckets.

The proposed complaint alleges Vitagene changed its name from Vitagene, Inc. to 1Health.io Inc. in October 2020. According to the proposed complaint, the company published revised privacy policies in April and December 2020 that apply to all the company's customers, including those who purchased products and services from the company solely before April 2020. The proposed complaint alleges that, compared to Vitagene's previous privacy policy, the company's 2020 privacy policies significantly expand the types of third parties with whom, and the purposes for which, the company may share consumers sensitive personal information. The company did not provide direct notice to consumers of the change, but it also did not implement the expanded

The proposed five-count complaint alleges that Vitagene violated section 5(a) of the FTC Act by misrepresenting the company's data security and privacy practices, and by unfairly making material retroactive changes to the company's policies regarding third-party sharing of sensitive personal information.

Proposed complaint Count I alleges
Vitagene deceived consumers by
misrepresenting that it exceeded
industry-standard security practices. On
a web page that Vitagene devoted to
describing its privacy practices,
Vitagene claimed that "[w]e use the
latest technology and exceed industrystandard security practices to protect
your privacy." The proposed complaint
alleges that Vitagene's public exposure
of consumers' Health Reports, raw
genetic data, and other personal
information in AWS S3 buckets until
July 2019 contradicted this claim.

Proposed complaint Count II alleges Vitagene deceptively claimed on multiple web pages that it stored consumers' DNA results without name or any other common identifying information. The proposed complaint alleges that this claim was deceptive because Vitagene stored consumers' DNA results with their names and other common identifying information.

Proposed complaint Count III alleges Vitagene deceptively claimed that it would remove all of a consumer's information if the consumer requested deletion of his or her data. Vitagene made this claim on a web page that Vitagene devoted to describing its privacy practices. The proposed complaint alleges that the claim was deceptive because, from approximately 2016 through July 1, 2019, Vitagene's lack of a data inventory made it impossible for the company to search comprehensively in response to consumers' requests for Vitagene to delete their data.

Proposed complaint Count IV alleges Vitagene deceived consumers by claiming on multiple web pages that it destroys consumers' physical DNA saliva samples shortly after analysis of them. The proposed complaint alleges that this claim was deceptive because, beginning in approximately December 2016, Vitagene did not have a contract provision with its genotyping laboratory partner requiring such destruction.

Proposed complaint Count V alleges it was unfair for Vitagene to post on its websites in April and December 2020 revised privacy policies that describe materially expanded practices for the company's sharing of consumers' sensitive health and genetic information with third parties—including the information of consumers who purchased products and services from Vitagene solely before April 2020—without taking any additional steps to notify consumers or obtain consumers' consent.

The proposed order contains provisions to address Vitagene's conduct and prevent it from engaging in the same or similar acts or practices in the future. Part I of the proposed order prohibits Vitagene from misrepresenting (1) the extent to which it meets or exceeds industry-standard security or privacy practices, (2) the extent to which it stores any Health Information (as defined in the order) with any other element of Personal Information (as also defined in the order), (3) the extent to which, or the purposes for which, it collects, uses, discloses, maintains, deletes, or destroys a consumer's (i) physical DNA sample or (ii) Personal Information upon request, (4) it is a member of, adheres to, complies with, is certified by, or otherwise participates in, any privacy or security program sponsored by a government entity or third party, (5) the extent to which it otherwise protects the privacy, security, availability, confidentiality, or integrity of Personal Information, or (6) it has received approval or authorization for its claims, products, or services from any government agency.

Part II prohibits Vitagene from disclosing Health Information to any Third Party (as defined in the order) unless the company obtains the Affirmative Express Consent (as also defined in the order) of the individual who is identifiable by the Health Information. Part III requires Vitagene to instruct any laboratory that collected physical DNA samples pursuant to a contract with Vitagene to destroy any such sample that the laboratory retained for more than 180 days after Vitagene accepted the results of the analysis of the sample.

Part IV requires Vitagene to establish, implement, and maintain a comprehensive information security program that protects the security, confidentiality, and integrity of Personal Information. Part V requires Vitagene to obtain initial and biennial data security assessments from a third-party assessor for twenty years. Part VI requires Vitagene to disclose all material facts to the assessor and prohibits Vitagene from misrepresenting any fact material to the assessments required by Part V.

Part VII requires Vitagene to submit to the Commission an annual certification that Vitagene has implemented the requirements of the Order and is not aware of any material noncompliance that has not been corrected or disclosed to the Commission. Part VIII requires Vitagene to submit a report to the Commission if it discovers any Covered Incident (as defined in the order).

Part IX requires Vitagene to pay \$75,000 in monetary relief. Part X provides that the Commission may use Vitagene's monetary relief payment to provide, and pay expenses related to the administration of, consumer redress. Part XI requires Vitagene to provide the Commission customer information to enable the Commission to efficiently administer consumer redress.

Parts XII—XV are reporting and compliance provisions. Part XII requires Vitagene to acknowledge receipt of the order and distribute it to persons with responsibilities relating to the subject matter of the order. Part XIII requires Vitagene to submit an initial compliance report to the Commission and notify the Commission of changes in Vitagene's corporate status. Part XIV requires Vitagene to create and retain certain documents relating to its compliance

with the order. Part XV requires that Vitagene provide the Commission additional information or compliance reports, as requested. Part XVI states that the proposed order will remain in effect for 20 years, with certain exceptions.

The purpose of this analysis is to aid public comment on the proposed order. It is not intended to constitute an official interpretation of the complaint or proposed order, or to modify in any way the proposed order's terms.

By direction of the Commission.

April J. Tabor,

Secretary.

[FR Doc. 2023-13329 Filed 6-22-23; 8:45 am]

BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-D-2204]

Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act." This draft guidance provides recommendations for industry and review staff on the formal dispute resolution and administrative hearings procedures for resolving scientific and/ or medical disputes between the Center for Drug Evaluation and Research (CDER) and requestors and sponsors of drugs that will be subject to a final administrative order (final order) under section 505G of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

DATES: Submit either electronic or written comments on the draft guidance by August 22, 2023 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA—2023—D—2204 for "Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240—402—7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the

information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993—0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Jung Lee, Center for Drug Evaluation and Research (HFD–600), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5494, Silver Spring, MD 20993, 301–796–3599.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled "Formal Dispute Resolution and Administrative Hearings of Final